Noncoding RNAs in Acute Myeloid Leukemia: From Key Regulators to Clinical Players. (11th October 2012)

• Record Type: Journal Article
• Authors: Fatica, Alessandro
• Other Names: Auberger Patrick Academic Editor.; Bydlowski Sergio Academic Editor.; Yu Jianhua Academic Editor.
• Is Part Of: Scientifica. Volume 2012(2012)
• Publication Date: 2012-10-11
• Subjects: Life sciences -- Periodicals; Biology -- Periodicals; Medicine -- Periodicals; Biological Science Disciplines; Medicine; Biology; Life sciences; Medicine; Periodicals; Electronic journals; Periodicals; 500
• DOI: 10.6064/2012/925758
• Languages: English
• ISSNs: 2090-908X

Abstract

Abstract : Recent analyses have shown that human cells transcribe almost their entire genomes, implying the existence of a huge mass of ncRNAs. At the present, microRNAs are the most investigated regulative non-coding RNAs. Several studies have demonstrated that microRNAs play a crucial role in hematopoietic differentiation and hematological malignancies, including acute myeloid leukemia (AML). Aberrant expression of microRNAs has been associated with specific genetic abnormalities and clinical outcome of patients with AML. In addition, since microRNAs can function as either oncogenes or tumor suppressor genes, the potential of using these molecules as therapeutic targets opens up new opportunities in the future of AML therapy. The recent demonstration that other regulatory ncRNAs, in addition to microRNAs, are involved in hematopoietic cell differentiation and diseases, suggests that they may also have a biological relevance in AML. This paper will describe the role of ncRNAs in AML and discuss the expectations for the use of ncRNAs in diagnosis, prognosis, and therapy of AML.